Divis Laboratories Ltd's Q3FY25 Quarter Results
- 04 Feb 2025
Result Summary
- Divis Laboratories Ltd reported a 1.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 23.1%.
- Its expenses for the quarter were down by 2.7% QoQ and up 14.6% YoY.
- The net profit increased 15.5% QoQ and increased 64.5% YoY.
- The earnings per share (EPS) of Divis Laboratories Ltd stood at 22.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2401.00 | 2444.00 | 1950.00 | -1.8% | 23.1% |
Total Expenses | 1675.00 | 1722.00 | 1461.00 | -2.7% | 14.6% |
Profit Before Tax | 726.00 | 722.00 | 489.00 | 0.6% | 48.5% |
Tax | 137.00 | 212.00 | 131.00 | -35.4% | 4.6% |
Profit After Tax | 589.00 | 510.00 | 358.00 | 15.5% | 64.5% |
Earnings Per Share | 22.20 | 19.20 | 13.50 | 15.6% | 64.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Divis Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacture, and sale of active pharmaceutical ingredients (APIs) and intermediates. The company is known for its strong research and development capabilities and has a significant presence in both domestic and international markets. Divis Laboratories is often recognized for its robust production facilities and adherence to stringent quality standards. While specific recent developments are not provided, the company operates in a sector characterized by rapid innovation and strict regulatory environments.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Divis Laboratories Ltd reported a total income of ₹2401.00 crores. This represents a marginal decrease of 1.8% compared to the previous quarter (Q2FY25), where the total income was ₹2444.00 crores. On a year-over-year basis, the total income increased significantly by 23.1% from ₹1950.00 crores in Q3FY24. This indicates a substantial growth in revenue over the year, highlighting the company's expanding business operations and market reach within the period.
Profitability
The company showed a positive trend in profitability, with a profit before tax (PBT) of ₹726.00 crores in Q3FY25, marking a slight increase of 0.6% from the previous quarter's PBT of ₹722.00 crores. Year-over-year, the PBT rose by 48.5% from ₹489.00 crores in Q3FY24 to ₹726.00 crores in Q3FY25. Following the payment of taxes amounting to ₹137.00 crores, which decreased by 35.4% QoQ, the profit after tax (PAT) stood at ₹589.00 crores. This reflects a notable increase of 15.5% from the previous quarter and a significant jump of 64.5% compared to the same period last year. Earnings per share (EPS) also increased in tandem with the PAT, rising from ₹19.20 in Q2FY25 to ₹22.20 in Q3FY25, and from ₹13.50 in Q3FY24, representing a 15.6% QoQ and a 64.4% YoY increase.
Operating Metrics
Total expenses for Divis Laboratories Ltd were recorded at ₹1675.00 crores in Q3FY25, showing a 2.7% decrease from ₹1722.00 crores in Q2FY25. Year-over-year, total expenses increased by 14.6% from ₹1461.00 crores in Q3FY24. This decline in expenses from the previous quarter, coupled with a significant YoY increase, reflects the company's operational adjustments and scaling over the year. The tax expenses saw a considerable reduction of 35.4% QoQ, from ₹212.00 crores to ₹137.00 crores, while experiencing a modest 4.6% increase YoY. These financial metrics underscore the company's operational efficiency and fiscal discipline in the reported quarter, aligning with the overall growth in profitability and revenue metrics.
